AUTHOR=Priyadarshini Masoom , Prabhu Vimalanand S. , Snedecor Sonya J. , Corman Shelby , Kuter Barbara J. , Nwankwo Chizoba , Chirovsky Diana , Myers Evan 

TITLE=Economic Value of Lost Productivity Attributable to Human Papillomavirus Cancer Mortality in the United States

JOURNAL=Frontiers in Public Health

VOLUME=8

YEAR=2021

URL=https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2020.624092

DOI=10.3389/fpubh.2020.624092

ISSN=2296-2565

ABSTRACT=<p><bold>Objectives:</bold> To estimate years of potential life lost (YPLL) and present value of future lost productivity (PVFLP) associated with premature mortality due to HPV-attributable cancers, specifically those targeted by nonavalent HPV (9vHPV) vaccination, in the United States (US) before vaccine use.</p><p><bold>Methods:</bold> YPLL was estimated from the reported number of deaths in 2017 due to HPV-related cancers, the proportion attributable to 9vHPV-targeted types, and age- and sex-specific US life expectancy. PVFLP was estimated as the product of YPLL by age- and sex-specific probability of labor force participation, annual wage, value of non-market labor, and fringe benefits markup factor.</p><p><bold>Results:</bold> An estimated 7,085 HPV-attributable cancer deaths occurred in 2017 accounting for 154,954 YPLL, with 6,482 deaths (91%) and 141,019 YPLL (91%) attributable to 9vHPV-targeted types. The estimated PVFLP was $3.8 billion for cancer deaths attributable to 9vHPV-targeted types (84% from women). The highest productivity burden was associated with cervical cancer in women and anal and oropharyngeal cancers in men.</p><p><bold>Conclusions:</bold> HPV-attributable cancer deaths are associated with a substantial economic burden in the US, much of which could be vaccine preventable.</p>